VivoSeq
Ophthalmology

Eye Disease

129

Pipeline Programs↗

25

Active Trials↗

53

Companies Involved↗

Eye Disease is a highly competitive landscape with 129 programs across 53 companies. The most active players are Rigel Pharmaceuticals, Aurinia Pharmaceuticals, Aldeyra Therapeutics, Inc.. 21 therapies are approved with 35 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

37/100

Mech. Concentration

11/100

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Rigel Pharmaceuticals

1 program

Phase 1Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

2 programs

Phase 2A

Aldeyra Therapeutics, Inc.

1 program

Phase 2K

Kala Pharmaceuticals, Inc.

1 program

Phase 2T

Telios Pharma, Inc.

1 program

Phase 2V

VivaVision Biotech, Inc

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical18

Alteplase

Roche

Potassium Iodide

Dawnrays Pharmaceutical (Holdings) Limited

Idebenone

Santhera Pharmaceuticals

Riboflavin

Cornea and Laser Eye Institute

Resveratrol

National Cancer Institute (NCI)

Phase 12

Liposomal Sirolimus

Instituto de Oftalmología Fundación Conde de Valenciana

JN002

Eye & ENT Hospital of Fudan University

Phase 253

Voclosporin

Aurinia Pharmaceuticals

CFH5633

Novartis

Anecortave Acetate

Alcon Research

Immune Globulin

CSL Behring

Active Comparator

Moderna

Phase 335

Aspirin

Bayer

Cyclosporine

Novartis

Acyclovir

Bp Consulting, Inc

Carboxymethylcellulose

AbbVie

Oxervate

Dompé Farmaceutici S.p.A

Approved21

Varenicline

Prism Pharmaceuticals

Pegcetacoplan

Apellis Pharmaceuticals

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phenylephrine

Exela Pharma Sciences, LLC.

Analysis

Modality Breakdown

95%

Small molecule

187 of 196 classified programs — the dominant modality here.

5%ALL OTHERSProtein / enzyme42%Monoclonal antibody21%Peptide21%Cell therapy1<1%

Small molecule leads; the ring shows all 196 classified programs, each share of the total. Modality classified for 100% of 201 pipeline programs.

Analysis

Trial Status

214

clinical trials

Completed151 · 71%
Unknown status22 · 10%
Recruiting16 · 7%
Terminated9 · 4%
Withdrawn6 · 3%
Not yet recruiting5 · 2%
Other5 · 2%

Clinical Trials

Trial Activity

214 trials

Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease
Recruiting·—·Phase 2·NCT04673643·128 enrolled
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
Recruiting·Roche logoRoche·Phase 4·NCT07025811·350 enrolled
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
Recruiting·VVivaVision Biotech, Inc·Phase 3·NCT06360133·700 enrolled
Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease.
Recruiting·KKhyber Teaching Hospital·Phase 4·NCT06939959·126 enrolled
A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
Recruiting·ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.·Phase 3·NCT06766357·360 enrolled
JN002 for the Treatment of Dry Eye Disease
Recruiting·EEye & ENT Hospital of Fudan University·Phase 1·NCT07245017·30 enrolled
A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study
Recruiting·MMedical University of Vienna·Phase 4·NCT07463950·25 enrolled
Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
Recruiting·LLunan Better Pharmaceutical Co., LTD.·Phase 3·NCT06879782·820 enrolled
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
Recruiting·AbbVie logoAbbVie·Phase 3·NCT07284381·250 enrolled
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
Recruiting·IInstituto Grifols, S.A.·Phase 2·NCT07264517·100 enrolled
Salivary Conductivity Screening for Dry Eye Disease and Sjögren's Syndrome
Recruiting·—·N/A·NCT06406933·200 enrolled
Evaluation of BTV100 in Subjects With Dry Eye Disease
Recruiting·BBioTheraVision, Inc.·Phase 2·NCT06543303·120 enrolled
Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease With Meibomian Gland Dysfunction
Recruiting·—·Phase 1/2·NCT06544447·135 enrolled
Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease
Recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 1/2·NCT07298811·40 enrolled
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
Recruiting·BBausch & Lomb Incorporated·Phase 2·NCT07128628·423 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)